Growth-hormone-axis peptides
CJC-1295: measurable hormone changes are not proof of broad health benefits
An evidence review of CJC-1295's growth-hormone-releasing activity, small early human studies, FDA safety concerns, and the gap between biomarkers and clinical outcomes.
How it is thought to work
Mechanism, without turning it into a promise
In plain language
CJC-1295 is designed to stimulate the body's growth-hormone signaling rather than supply growth hormone directly.
Technical context
It is a long-acting growth-hormone-releasing hormone analog. Early trials measured GH and IGF-1 concentrations, not broad claims about longevity or performance.
What remains uncertain
A biomarker response does not show that people feel better, recover faster, live longer, or avoid downstream risks.
Evidence map
What has actually been studied
Two small randomized ascending-dose trials
A 2006 report found sustained dose-dependent increases in GH and IGF-1 in healthy adults.
How to interpret it: This demonstrates pharmacologic activity. It does not establish clinical benefit for anti-aging, body composition, or injury recovery.
Important limits
- Small early-stage studies
- Short follow-up
- Healthy participants
- Biomarker endpoints
Safety center
Known risks and important unknowns
What is known
- Short early trials cannot define uncommon or long-latency adverse effects.
Serious concerns
- FDA reports serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction.
What remains unknown
- Long-term endocrine, metabolic, cardiovascular, and tumor-related consequences are not adequately characterized for unapproved use.
Product-quality questions
- Products labeled with or without DAC are not interchangeable, and an online label does not establish identity or purity.
When to involve a clinician: Hormonal symptoms or concerns require assessment by a licensed clinician; a single biomarker should not be interpreted in isolation.
What people report
Useful questions, not clinical proof
- Online users may describe sleep, recovery, body-composition, or appetite changes.
- These subjective reports do not demonstrate which product was present, whether hormone changes caused the experience, or whether harms were missed.
How to read it
Keep these distinctions visible
- With-DAC and no-DAC discussions should not be collapsed into one product claim.
- Biomarker movement is an intermediate finding, not a patient-important outcome.
Common questions
Answers that preserve the uncertainty
Does higher IGF-1 prove CJC-1295 improves recovery?
No. It proves a biomarker changed in the study setting. Recovery requires direct, controlled clinical outcomes.
Was CJC-1295 shown to be safe in humans?
Only limited short-term data exist, and FDA has identified serious associated adverse events. That is not a complete safety profile.
Are CJC-1295 with DAC and no-DAC the same?
No. Modification changes pharmacologic behavior, so evidence and identity should be tracked separately.
Sources
What this page relies on
- 1. Bulk drug substances that may present significant safety risks
U.S. Food and Drug Administration - Accessed 2026-08-04 - Supports: FDA safety concerns, human evidence gaps, quality uncertainty
- 2. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
PubMed / Journal of Clinical Endocrinology and Metabolism - Accessed 2026-08-04 - Supports: study design, GH and IGF-1 findings, short-term tolerability, limitations